Table 1.
Characteristics of the study population.
| N= 803 | |
|---|---|
| Age, years | 68.3 (6.2) |
| Women | 410 (51.1) |
| Pre-existing microbleeds | 195 (24.3) |
| Strictly lobar | 129 (16.1) |
| Deep or infratentorial | 66 (8.2) |
| Incident microbleeds | 78 (9.7) |
| Strictly lobar | 49 (6.1) |
| Deep or infratentorial | 29 (3.6) |
| Baseline white matter lesion volume, mL | 3.7 (2.2; 7.1) |
| White matter lesions volume progressiona | 0.18 (0.03; 0.53) |
| Pre-existing lacunes | 59 (7.3) |
| Incident lacunes | 20 (2.5) |
| Scan interval, years | 3.4 (0.2) |
| Intracranial volume, mL | 1119.1 (115.6) |
| Systolic blood pressure, mmHg | 143.7 (18.0) |
| Diastolic blood pressure, mmHg | 80.7 (10.3) |
| Total cholesterol, mmol/L | 5.7 (1.0) |
| High-density lipoprotein cholesterol, mmol/L | 1.4 (0.4) |
| Smoking | 564 (70.2) |
| Diabetes mellitus | 64 (8.0) |
| Lipid lowering medication use | 170 (21.2) |
| Antihypertensive medication use | 282 (35.1) |
| Antiplatelet medication use | 207 (25.8) |
| Apolipoprotein E ε4 carriership | 198 (24.7) |
Data are presented as mean (standard deviation) for continuous variables, number (%) for categorical variables.
a
White matter lesions are presented as median (interquartile range). The following variables had missing data: systolic and diastolic blood pressure N=3, total and high-density lipoprotein cholesterol N=6, smoking N=8, diabetes mellitus N=11, lipid lowering and antihypertensive medication N=8, apolipoprotein E genotype N=4.